Sugi Predict

Sugi Predict / Compounds / SCHEMBL3154476

SCHEMBL3154476

SCHEMBL3154476

c1ccc(OCN2CCCCC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 8/20 0.57
▸ CYP2D6 P10635 1/20 0.57
▸ TSHR P16473 1/20 0.57
▸ HIF1A Q16665 1/20 0.57
▸ LTA4H P09960 4/20 0.56
▸ ESR1 P03372 1/20 0.55
▸ ESR2 Q92731 1/20 0.55
▸ CXCR1 P25024 1/20 0.55
▸ KDM4E B2RXH2 2/20 0.54
▸ KCNH2 Q12809 2/20 0.53
▸ HRH1 P35367 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ HRH4 Q9H3N8 1/20 0.50
▸ BACE1 P56817 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12486958 0.98 LTA4H (0.58) HRH3CYP2D6TSHRHIF1ALTA4H
SCHEMBL2300940 0.94 LTA4H (0.53) HRH3CYP2D6TSHRHIF1ALTA4H
SCHEMBL30272620 0.80 HRH3 (0.63) HRH3LTA4HKDM4EALDH1A1
SCHEMBL5656590 0.80 HRH3 (0.43) HRH3CYP2D6TSHRESR1ESR2
SCHEMBL3163559 0.80 HRH3 (0.63) HRH3LTA4HESR1ESR2CXCR1
SCHEMBL255055 0.80 ESR1 (0.58) HRH3TSHRLTA4HESR1ESR2
SCHEMBL3951411 0.80 LTA4H (0.83) HRH3LTA4HKDM4EKCNH2HRH1
SCHEMBL5870409 0.80 LTA4H (0.83) HRH3LTA4HKDM4EKCNH2HRH1
SCHEMBL12403566 0.79 DRD2 (0.68) HRH3CYP2D6KCNH2HRH1SMN1; SMN2
SCHEMBL2823877 0.79 HRH3 (0.87) HRH3LTA4HKDM4EKCNH2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0577470-B1 2-Amino-N-[[[4-(aminocarbonyl)pyrimidin-2-yl]amino]alkyl]-pyrimidine-4-carboxamide derivates, their preparation and their use in therapeutics SYNTHELABO (FR) 1995-05-24 — — EP claimed
US-5330985-A Adrenergic blocking agents; urogenital disorders SYNTHELABO (FR) 1994-07-19 — — US claimed
US-5169855-A PIPERIDINE ETHER DERIVATIVES AS PSYCHOTROPIC DRUGS OR PLANT FUNGICIDES DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1992-12-08 — — US claimed
US-4438116-A Quinoxalinyloxy-amino-propanol compounds with blood pressure lowering and β-blocking properties, their use and pharmaceutical compositions containing them BOEHRINGER MANNHEIM GMBH (DE) 1984-03-20 — — US claimed
EP-0019918-B1 DERIVATIVES OF AMINO-PROPANOL, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Roche Diagnostics GmbH (DE) 1983-09-07 — — EP claimed
WO-2025125888-A1 ARIPIPRAZOLE AND TRAMADOL COMPOSITIONS WITH POTENTIATION EFFECTS AND HIGH ANALGESIC EFFICACY USEFUL FOR THE TREATMENT OF NEUROPATHIC PAIN CENTRO DE INVESTIGACIÓN Y DE ESTUDIOS AVANZADOS DEL I.P.N. (MX) 2025-06-19 — — WO disclosed
EP-4329881-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF Vanqua Bio, Inc. (US) 2024-03-06 — — EP disclosed
WO-2022232383-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2022-11-03 — — WO disclosed
US-9963452-B2 Methods, compounds, and compositions for inhibition of ROS AUGUSTA PHARMACEUTICALS INC. (US) 2018-05-08 — — US disclosed
US-20180050997-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. 2018-02-22 — — US disclosed
US-20170312273-A1 METHODS OF USING FASN INHIBITORS FORMA THERAPEUTICS, INC. 2017-11-02 — — US disclosed
US-9676721-B2 Compounds and compositions for the inhibition of NAMPT FORMA TM, LLC (US) 2017-06-13 — — US disclosed
US-5330985-A Adrenergic blocking agents; urogenital disorders SYNTHELABO (FR) 1994-07-19 — — US disclosed
US-5330985-A Adrenergic blocking agents; urogenital disorders SYNTHELABO (FR) 1994-07-19 — — US disclosed
EP-0577470-A1 2-Amino-N-[[[4-(aminocarbonyl)pyrimidin-2-yl]amino]alkyl]-pyrimidine-4-carboxamide derivates, their preparation and their use in therapeutics SYNTHELABO (FR) 1994-01-05 — — EP disclosed
EP-0351282-B1 (1-Hydroxy-2-piperidinyl alkyl)-2-indolone, 2-quinolinones, 2-benzo[b]azepinone, 2-benzimidazolone and 2-quinazolinone derivatives, their preparation and therapeutical use SYNTHELABO (FR) 1993-10-27 — — EP disclosed
EP-0351282-A1 (1-Hydroxy-2-piperidinyl alkyl)-2-indolone, 2-quinolinones, 2-benzo[b]azepinone, 2-benzimidazolone and 2-quinazolinone derivatives, their preparation and therapeutical use SYNTHELABO (FR) 1990-01-17 — — EP disclosed
EP-0019918-B1 DERIVATIVES OF AMINO-PROPANOL, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Roche Diagnostics GmbH (DE) 1983-09-07 — — EP disclosed
US-4348401-A ANTIHISTAMINIC, ANTIEDEMIC, ANTIPHLOGISTIC BOEHRINGER MANNHEIM GMBH (DE) 1982-09-07 — — US disclosed
US-4146630-A HYPOTENSIVE AGENTS BOEHRINGER MANNHEIM GMBH (DE) 1979-03-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180050997-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FASN, FABP1, SCD HRH3 4167/4885CYP2D6 588/4885TSHR 3727/4885
US-20170312273-A1 METHODS OF USING FASN INHIBITORS FASN, IL1RN, CCR1 HRH3 1779/4885CYP2D6 2569/4885TSHR 3453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.